Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Palovarotene (brand name Sohonos) is the first and only treatment approved by the FDA for fibrodysplasia ossificans progressiva, an ultra-rare genetic condition in which bone forms in muscles, tendons, and ligaments. This oral retinoid is approved to reduce new abnormal bone growth (heterotopic ossification) in females 8 years and older and males 10 years and older, and it carries important safety warnings, including growth plate closure in growing children. Beyond approved therapy, care typically focuses on short courses of corticosteroids at the start of flare-ups, fall prevention, avoiding intramuscular injections and biopsies, and monitoring breathing and jaw function. Other drugs, such as garetosmab, remain investigational and are not yet approved. There are several important factors to consider, including eligibility, dosing, and side effects, so see below to understand more.
If you or someone you love is dealing with unexplained swelling, stiffening joints, or lumps that seem to harden over time, the details matter, and waiting rarely makes answers clearer. A free, instant, online symptom check can help you organize what you are experiencing, surface possible explanations worth discussing, and point you toward the right type of specialist. It takes only a few minutes, requires no insurance or appointment, and gives you a clearer starting point for your next conversation with a clinician.
Last reviewed for medical accuracy: 09/24/2025
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition where muscle and connective tissue gradually turn into bone. This “second skeleton” severely limits movement, affects daily life, and can lead to complications such as respiratory problems. Until recently, treatment options focused mainly on managing symptoms and slowing flare-ups. Today, patients and families have a landmark therapy that directly targets the disease process.
Palovarotene is the first—and currently the only—medication approved by health authorities specifically for fibrodysplasia ossificans progressiva treatment. Here’s what you need to know:
Even with palovarotene, comprehensive care remains critical. Supportive treatments help manage flare-ups and maintain function:
• Acute flare-up care
• Pain relief and muscle relaxation
• Physical therapy and activity
• Respiratory and nutritional support
• Surgical interventions
Research into fibrodysplasia ossificans progressiva treatment continues in specialized centers:
While promising, these remain experimental. Participation in a clinical trial often requires evaluation at an FOP-focused research center.
Living well with FOP means combining medical therapy with day-to-day strategies:
If you’re unsure whether your aches, swellings, or stiffness could signal a flare-up, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to gather guidance before you talk with your care team.
Fibrodysplasia ossificans progressiva treatment continues to evolve. Palovarotene offers new hope, but managing FOP is a lifelong partnership between you and your healthcare providers. Always speak to a doctor about:
For anything serious or life threatening—uncontrolled pain, breathing difficulties, or sudden loss of function—seek medical attention immediately. Your doctor knows your history best and will help you choose the safest, most effective path forward.
(References)
* Newton MC, Allen PW, Ryan DC. Fibrodysplasia ossificans progressiva. Br J Anaesth. 1990 Feb;64(2):246-50. doi: 10.1093/bja/64.2.246. PMID: 2317429.
* Mahboubi S, Glaser DL, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva. Pediatr Radiol. 2001 May;31(5):307-14. doi: 10.1007/s002470100447. PMID: 11379597.
* Järvinen TA, Järvinen TL, Kääriäinen M, Kalimo H, Järvinen M. Muscle injuries: biology and treatment. Am J Sports Med. 2005 May;33(5):745-64. doi: 10.1177/0363546505274714. PMID: 15851777.
* Järvinen TA, Järvinen TL, Kääriäinen M, Aärimaa V, Vaittinen S, Kalimo H, Järvinen M. Muscle injuries: optimising recovery. Best Pract Res Clin Rheumatol. 2007 Apr;21(2):317-31. doi: 10.1016/j.berh.2006.12.004. PMID: 17512485.
* Hoyer-Kuhn H, Schönau E. Pharmacotherapy in Rare Skeletal Diseases. Handb Exp Pharmacol. 2020;261:87-104. doi: 10.1007/164_2019_305. PMID: 32519163.
* Hoy SM. Palovarotene: First Approval. Drugs. 2022 Apr;82(6):711-716. doi: 10.1007/s40265-022-01709-z. PMID: 35384641.
* Hwang CD, Pagani CA, Nunez JH, Cherief M, Qin Q, Gomez-Salazar M, Kadaikal B, Kang H, Chowdary AR, Patel N, James AW, Levi B. Contemporary perspectives on heterotopic ossification. JCI Insight. 2022 Jul 22;7(14). doi: 10.1172/jci.insight.158996. Epub 2022 Jul 22. PMID: 35866484; PMCID: PMC9431693.
* Di Rocco M, Forleo-Neto E, Pignolo RJ, Keen R, Orcel P, Funck-Brentano T, Roux C, Kolta S, Madeo A, Bubbear JS, Tabarkiewicz J, Szczepanek M, Bachiller-Corral J, Cheung AM, Dahir KM, Botman E, Raijmakers PG, Al Mukaddam M, Tile L, Portal-Celhay C, Sarkar N, Hou P, Musser BJ, Boyapati A, Mohammadi K, Mellis SJ, Rankin AJ, Economides AN, Trotter DG, Herman GA, O'Meara SJ, DelGizzi R, Weinreich DM, Yancopoulos GD, Eekhoff EMW, Kaplan FS. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2023 Oct;29(10):2615-2624. doi: 10.1038/s41591-023-02561-8. Epub 2023 Sep 28. PMID: 37770652; PMCID: PMC10579054.
* Keen R, Dahir KM, McGinniss J, Sanchez RJ, Mellis S, Economides AN, Di Rocco M, Orcel P, Roux C, Tabarkiewicz J, Bachiller-Corral J, Cheung AM, Al Mukaddam M, Mohammadi K, Gu J, Srinivasan D, Trotter DG, Eekhoff EMW, Kaplan FS, Pignolo RJ. Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial. J Bone Miner Res. 2024 Sep 26;39(10):1486-1492. doi: 10.1093/jbmr/zjae140. PMID: 39216107; PMCID: PMC11425702.
* Kuenzler KA, Schwendimann A, Schumann P, Essig H, Ferrari RM. Fibrodysplasia Ossificans Progressiva. Swiss Dent J. 2026 Jul 15;136(2):77-87. doi: 10.61872/sdj-2026-02-07. Epub 2026 Jul 15. PMID: 42455132.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.